Denmark could help more 患者s with Wegovy cost if Novo 支払う／賃金s too -大臣
By Jacob Gronholt-Pedersen
COPENHAGEN, Dec 1 (Reuters) - Denmark's 政府 could help cover the cost of hugely popular 負わせる-loss 麻薬 Wegovy for more people with 厳しい obesity if its Danish 製造者, Novo Nordisk, also 与える／捧げるs some 基金ing, Health 大臣 Sophie Lohde said on Friday.
Her comments are the 最新の 調印する that 政府s are 重さを計るing the cost of 支払う／賃金ing for the 週刊誌 注射 against the 利益s for the economy and healthcare system of having a healthier 全住民.
Wegovy, the first-to-market in a new class of 高度に 効果的な 負わせる-loss 麻薬s, has also been 設立する to have a （疑いを）晴らす cardiovascular 利益.
Millions of 患者s have already paid for the 麻薬 which can cost as much as $1,000 per month in the 部隊d 明言する／公表するs, the biggest market in which it is 現在／一般に 利用できる.
Wegovy has also been 開始する，打ち上げるd in Denmark, Norway, Germany, Britain and アイスランド, although 供給（する）s are constrained.
But Novo now 目的（とする）s to 納得させる European 政府s that have 伝統的に 扱う／治療するd 負わせる-loss 治療s as lifestyle 麻薬s to 支払う／賃金 for Wegovy for those who need it most or who cannot afford it.
In Denmark, where Novo Nordisk is headquartered, a 危険-株ing 計画／陰謀 in 操作／手術 since last year 許すs the 明言する／公表する to reimburse the cost of Wegovy for a 確かな number of people with 厳しい obesity.
Health 大臣 Lohde said in 議会 on Friday that if prescriptions for 患者s in that 的 group 越える the agreed number, the 付加 cost will be 株d between Novo Nordisk and the 明言する／公表する, but did not (a)手の込んだ／(v)詳述する.
Novo 確認するd an 使用／適用 for reimbursement of Wegovy was 存在 reviewed by the Danish 薬／医学s 機関 but dec lined to give その上の 詳細（に述べる）s.
"We continue to hope that a 解答 can be 設立する as in other countries, where 接近 to 医薬 against 厳しい obesity is 確実にするd through reimbursements for a 限られた／立憲的な group of 患者s," the company said in a 声明.
Denmark's largest 私的な health 保険会社 said in April it will stop reimbursing the cost of 負わせる loss 医薬 from January next year 予定 to high 需要・要求する.
Danes 現在／一般に 支払う／賃金 1,300-2,300 Danish 栄冠を与えるs ($189-$335) a month for the 麻薬.
The Danish 薬／医学s 機関 last year 拒絶するd an 使用／適用 from Novo for reimbursement for 患者s with a 団体／死体 集まり 索引 (BMI) over 30 and co-morbidities.
The Danish health 省 said in August that reimbursing Wegovy for the 概略で 900,000 Danes with a BMI of 30 or above would cost 23.9-27.9 billion Danish 栄冠を与えるs each year. ($1 = 6.8610 Danish 栄冠を与えるs) (報告（する）／憶測ing by Jacob Gronholt-Pedersen; Editing by Catherine Evans)
